Brief: CStone Pharmaceuticals Posts HY IFRS Revenue RMB79.4 MLN
26/08/2021 16:01
Aug 26 (Reuters) - CStone Pharmaceuticals 2616.HK :
* HY IFRS REVENUE RMB79.4 MILLION
* HY IFRS LOSS RMB773.9 MILLION VERSUS LOSS RMB671.2 MILLION
* EXPECT TO GET NDA APPROVAL IN MAINLAND CHINA FOR
IVOSIDENIB FOR
R/R AML IN Q4 2021 OR Q1 2022
Source text for Eikon: ID:nHKSbkfGtC
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026